| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | 3.422 | 5.386 | 13.082 | 21.617 | 33.407 | 61.699 |
| Total Income - EUR | - | - | - | - | 3.422 | 5.386 | 13.082 | 21.617 | 33.407 | 61.699 |
| Total Expenses - EUR | - | - | - | - | 1.385 | 2.934 | 2.807 | 4.516 | 16.834 | 20.859 |
| Gross Profit/Loss - EUR | - | - | - | - | 2.037 | 2.452 | 10.275 | 17.101 | 16.574 | 40.840 |
| Net Profit/Loss - EUR | - | - | - | - | 1.935 | 2.299 | 9.883 | 16.453 | 13.614 | 38.988 |
| Employees | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 1 |
Check the financial reports for the company - Quadrant Oncology S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | 7.884 | 5.614 | 3.416 | 2.523 | 838 | 523 |
| Current Assets | - | - | - | - | 1.876 | 2.228 | 8.608 | 22.162 | 14.120 | 40.308 |
| Inventories | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | - | 0 | 0 | 0 | 375 | 0 | 26.301 |
| Cash | - | - | - | - | 1.876 | 2.228 | 8.608 | 21.787 | 14.120 | 14.008 |
| Shareholders Funds | - | - | - | - | 1.977 | 4.238 | 9.931 | 16.501 | 13.662 | 39.037 |
| Social Capital | - | - | - | - | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | 7.784 | 3.604 | 2.093 | 8.183 | 1.296 | 1.795 |
| Income in Advance | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Quadrant Oncology S.r.l.